Defining the Role of the Skin Microbiome in Immune-related Adverse Events
NCT04734704 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 175
Last updated 2021-02-02
Summary
The skin microbiome has been implicated in several cutaneous autoimmune pathologies such as psoriasis and atopic dermatitis. However, its role in vitiligo and vitiligo lesions occuring in patients receiving anti-PD-1 for metastatic melanoma
Conditions
- Vitiligo
- Skin Melanoma
Interventions
- PROCEDURE
-
skin swabs at lesional and non-lesional sites
It will be examined in patients skin swabs sampled at lesional and non-lesional sites
- PROCEDURE
-
skin swabs on skin
It will be examined in patients skin swabs sampled on skin
Sponsors & Collaborators
-
Centre National de la Recherche Scientifique, France
collaborator OTHER -
University Hospital, Bordeaux
lead OTHER
Principal Investigators
-
Julien SENESCHAL, MD, PhD · University Hospital, Bordeaux
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-05-01
- Primary Completion
- 2023-05-01
- Completion
- 2023-05-01
Countries
- France
Study Locations
More Related Trials
-
Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma
NCT05867004 ·Status: RECRUITING
-
Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
NCT01264731 ·Status: COMPLETED ·Phase: PHASE1
-
Radiation and Combination Immunotherapy for Melanoma
NCT03850691 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
NCT04708418 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Predicting Response to Immunotherapy for Melanoma With Gut Microbiome and Metabolomics
NCT03643289 ·Status: UNKNOWN
-
Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma
NCT03084640 ·Status: COMPLETED ·Phase: PHASE1
-
Pruritus and Melanoma and Cutaneous Carcinomas Treated With Immunotherapy
NCT04365244 ·Status: COMPLETED
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
NCT06295159 ·Status: RECRUITING ·Phase: PHASE2
-
Immune Profiles Evolution Under Immunotherapy for Melanoma
NCT04576429 ·Status: RECRUITING ·Phase: NA
-
Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors
NCT04253080 ·Status: COMPLETED ·Phase: NA
-
Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced Melanoma
NCT02938728 ·Status: UNKNOWN
-
Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention
NCT03817125 ·Status: COMPLETED ·Phase: PHASE1
-
Cryoablation+Ipilimumab+Nivolumab in Melanoma
NCT05779423 ·Status: RECRUITING ·Phase: PHASE2
-
Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face
NCT01720407 ·Status: COMPLETED ·Phase: PHASE3
-
Fecal Microbiota Transplant (FMT) in Melanoma Patients
NCT03341143 ·Status: COMPLETED ·Phase: PHASE2
-
Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)
NCT03407170 ·Status: TERMINATED ·Phase: PHASE2
-
Pembrolizumab and EDP1503 in Advanced Melanoma
NCT03595683 ·Status: TERMINATED ·Phase: PHASE2
-
The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma
NCT04017897 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma
NCT05751928 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Advanced Non-invasive Diagnostics for Early Cutaneous Tumor Diagnosis, Clinical-therapeutic and Economic Management
NCT04789421 ·Status: COMPLETED ·Phase: NA
-
A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer
NCT04099446 ·Status: WITHDRAWN
-
Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy
NCT02680184 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions
NCT00091689 ·Status: COMPLETED ·Phase: PHASE1
-
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
NCT04960618 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)
NCT03284424 ·Status: COMPLETED ·Phase: PHASE2